Focus: Peptilogics is a publicly-traded biotechnology company focused on peptide therapeutics, with a pipeline concentrated in neurology and infectious disease indications. The company operates at a mid-cap biotech scale with limited disclosed employee and financial data.
Profile data last refreshed 6h ago · AI intelligence enriched 2mo ago
Peptilogics offers niche peptide expertise and public-company credibility, but opacity around financials, minimal hiring, and early pipeline stage present career risk for those seeking stability or rapid advancement.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Peptilogics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Peptilogics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
University of Cincinnati launches clinical trial to test new drug for prosthetic joint infections - News-Medical
University of Cincinnati launches clinical trial to test new drug for prosthetic joint infections News-Medical
Peptilogics begins trial of drug designed to cure medical device-related infections - Medical Economics
Peptilogics begins trial of drug designed to cure medical device-related infections Medical Economics
Peptilogics Begins Pivotal Trial of First-Ever Drug Designed to Cure Medical Device-Related Infections - Business Wire
Peptilogics Begins Pivotal Trial of First-Ever Drug Designed to Cure Medical Device-Related Infections Business Wire
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of a First-in-Human Engineered Cationic Peptide, PLG0206, Intravenously Administered in Healthy Subjects.
Engineered peptide PLG0206 overcomes limitations of a challenging antimicrobial drug class.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo